Endothelial TFEB (Transcription Factor EB) Restrains IKK (IκB Kinase)-p65 Pathway to Attenuate Vascular Inflammation in Diabetic db/db Mice.


Journal

Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803

Informations de publication

Date de publication:
04 2019
Historique:
pubmed: 1 3 2019
medline: 14 1 2020
entrez: 1 3 2019
Statut: ppublish

Résumé

Objective- TFEB (transcription factor EB) was recently reported to be induced by atheroprotective laminar flow and play an anti-atherosclerotic role by inhibiting inflammation in endothelial cells (ECs). This study aims to investigate whether TFEB regulates endothelial inflammation in diabetic db/db mice and the molecular mechanisms involved. Approach and Results- Endothelial denudation shows that TFEB is mainly expressed in ECs in mouse aortas. Western blotting shows TFEB total protein level decreases whereas the p-TFEB S142 (phosphorylated form of TFEB) increases in db/db mouse aortas, suggesting a decreased TFEB activity. Adenoviral TFEB overexpression reduces endothelial inflammation as evidenced by decreased expression of vascular inflammatory markers in db/db mouse aortas, and reduced expression of a wide range of adhesion molecules and chemokines in human umbilical vein ECs. Monocyte attachment assay shows TFEB suppresses monocyte adhesion to human umbilical vein ECs. RNA sequencing of TFEB-overexpressed human umbilical vein ECs suggested TFEB inhibits NF-κB (nuclear factor-kappa B) signaling. Indeed, luciferase assay shows TFEB suppresses NF-κB transcriptional activity. Mechanistically, TFEB suppresses IKK (IκB kinase) activity to protect IκB-α from degradation, leading to reduced p65 nuclear translocation. Inhibition of IKK by PS-1145 abolished TFEB silencing-induced inflammation in human umbilical vein ECs. Lastly, we identified KLF2 (Krüppel-like factor 2) upregulates TFEB expression and promoter activity. Laminar flow experiment showed that KLF2 is required for TFEB induction by laminar flow and TFEB is an anti-inflammatory effector downstream of laminar flow-KLF2 signaling in ECs. Conclusions- These findings suggest that TFEB exerts anti-inflammatory effects in diabetic mice and such function in ECs is achieved by inhibiting IKK activity and increasing IκBα level to suppress NF-κB activity. KLF2 mediates TFEB upregulation in response to laminar flow.

Identifiants

pubmed: 30816805
doi: 10.1161/ATVBAHA.119.312316
doi:

Substances chimiques

Basic Helix-Loop-Helix Leucine Zipper Transcription Factors 0
Klf2 protein, mouse 0
Kruppel-Like Transcription Factors 0
RELA protein, human 0
Receptors, Leptin 0
Recombinant Proteins 0
Rela protein, mouse 0
TFEB protein, human 0
Tcfeb protein, mouse 0
Transcription Factor RelA 0
leptin receptor, mouse 0
I-kappa B Kinase EC 2.7.11.10

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

719-730

Auteurs

Wencong Song (W)

From the Institute of Vascular Medicine, Shenzhen Research Institute and Li Ka Shing Institute of Health Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L., Y.H.).
School of Biomedical Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L.,Y.H.), Chinese University of Hong Kong, China.

Cheng-Lin Zhang (CL)

From the Institute of Vascular Medicine, Shenzhen Research Institute and Li Ka Shing Institute of Health Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L., Y.H.).
School of Biomedical Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L.,Y.H.), Chinese University of Hong Kong, China.

Lingshan Gou (L)

From the Institute of Vascular Medicine, Shenzhen Research Institute and Li Ka Shing Institute of Health Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L., Y.H.).
School of Biomedical Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L.,Y.H.), Chinese University of Hong Kong, China.

Lei He (L)

From the Institute of Vascular Medicine, Shenzhen Research Institute and Li Ka Shing Institute of Health Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L., Y.H.).
School of Biomedical Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L.,Y.H.), Chinese University of Hong Kong, China.

Yao-Yu Gong (YY)

From the Institute of Vascular Medicine, Shenzhen Research Institute and Li Ka Shing Institute of Health Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L., Y.H.).
School of Biomedical Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L.,Y.H.), Chinese University of Hong Kong, China.

Dan Qu (D)

From the Institute of Vascular Medicine, Shenzhen Research Institute and Li Ka Shing Institute of Health Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L., Y.H.).
School of Biomedical Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L.,Y.H.), Chinese University of Hong Kong, China.

Lei Zhao (L)

From the Institute of Vascular Medicine, Shenzhen Research Institute and Li Ka Shing Institute of Health Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L., Y.H.).
School of Biomedical Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L.,Y.H.), Chinese University of Hong Kong, China.

Nana Jin (N)

School of Life Sciences (N.J., T.F.C.), Chinese University of Hong Kong, China.

Ting Fung Chan (TF)

School of Life Sciences (N.J., T.F.C.), Chinese University of Hong Kong, China.

Li Wang (L)

From the Institute of Vascular Medicine, Shenzhen Research Institute and Li Ka Shing Institute of Health Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L., Y.H.).
School of Biomedical Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L.,Y.H.), Chinese University of Hong Kong, China.

Xiao Yu Tian (XY)

From the Institute of Vascular Medicine, Shenzhen Research Institute and Li Ka Shing Institute of Health Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L., Y.H.).
School of Biomedical Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L.,Y.H.), Chinese University of Hong Kong, China.

Jiang-Yun Luo (JY)

From the Institute of Vascular Medicine, Shenzhen Research Institute and Li Ka Shing Institute of Health Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L., Y.H.).
School of Biomedical Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L.,Y.H.), Chinese University of Hong Kong, China.

Yu Huang (Y)

From the Institute of Vascular Medicine, Shenzhen Research Institute and Li Ka Shing Institute of Health Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L., Y.H.).
School of Biomedical Sciences (W.S., C.-L.Z., L.G., L.H., Y.-Y.G., Q.D., L.Z., L.W., X.Y.T., J.-Y.L.,Y.H.), Chinese University of Hong Kong, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH